Expert panel consensus produced a set of genomics-based disease categories from the two systems' morphology-based categories.
Heme Today
Heme Today covers the latest news and analyses in bleeding, clotting, red blood cell, and iron disorders for hematologists and oncologists focused on bleeding disorders.
Advertisement
Latest News
The favorable effects from pharmacologic iron restriction may also be enhanced when used with an erythroid maturation agent.
Analysts advise that CMML that features AML-associated mutations should undergo management approaches typically used for AML.
Clinicians seek alternatives to biopsy for clinically evaluating bone marrow mutations in cytopenic patients.
A retrospective study's insights help inform timing decisions regarding allogenic HCT in patients with MDS or CMML.
Investigators examined patients' baseline transfusion burdens and erythropoietin levels for correlations with agent response.
The COMMANDS trial data underscore luspatercept as the preferred treatment for disease not previously exposed to ESAs.
A cohort lifetime study from Hamda Khan, MA, and Jason Hodges, PhD, MA, follows patients from pediatric into adult SCD care.
A phase II trial evaluated use of the thrombopoietin receptor agonist in patients with at least one prior therapy.
Most of the research performed up to this point on the influence of clonal dynamics in MDS has focused on high-risk disease.
A majority of patients in the study had complete remission of disease within bone marrow with the combination therapy.
Advertisement
Blood Cancer Awareness Month
A phase II trial calculated a 4-year event-free survival rate of 96% and overall survival rate of 100% from the combination.
Differences were identified between patient racial groups and by urban versus rural populations.
A magnetic resonance imaging study has compared tissue iron levels and biventricular function between the two conditions.
MDS Roundtables
Expert Interviews on Hematology
Conference Coverage
Heme Today reports from the EHA 2024 Hybrid Congress the latest findings in hematology research and management.
Highlighting the latest news and experts in pediatric hematology and oncology from the 2024 ASPHO Conference in Seattle.
Our editors are covering data on transplantation and cellular therapies from the 2024 Tandem Meetings of ASTCT® and ...
The editors of Heme Today review major presentations on classical hematology from the 2023 ASH Annual Meeting & ...
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.